Quick Answer
Nautilus Biotechnology, Inc. reported Cash And Cash Equivalents At Carrying Value of $12.39 million for the year ending 2025.
- Nautilus Biotechnology, Inc. showed a decrease of -55.2% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Nautilus Biotechnology, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $288.39 million | Q3 2021: $190.24 million | Q1 2022: $188.62 million | Q2 2022: $210.35 million | Q3 2022: $188.93 million | Q1 2023: $88.51 million | Q2 2023: $72.14 million | Q3 2023: $74.10 million | Q1 2024: $25.73 million | Q2 2024: $24.89 million | Q3 2024: $4.41 million | Q1 2025: $33.24 million | Q2 2025: $34.46 million | Q3 2025: $23.88 million.
- Over the full 6 years of available data (2020 to 2025), Nautilus Biotechnology, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 66.2%.
- Historical annual values: Fiscal year 2025: $12.39 million | Fiscal year 2024: $27.65 million | Fiscal year 2023: $19.40 million | Fiscal year 2022: $114.52 million | Fiscal year 2021: $185.62 million | Fiscal year 2020: $36.61 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: